Differences in effects of oncogenes on sensitivity to anticancer drugs

Related Experiment Video

Updated: Aug 17, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Tomoyuki Hamamoto1, Keiji Suzuki, Hitoshi Sasaki

  • 1Department of Hospital Pharmacy, Nagasaki University School of Medicine, Japan.

Journal of Radiation Research
|July 1, 2005
PubMed

Insights

Oncogene expression influences anticancer drug sensitivity. Certain oncogenes like H-ras can cause drug resistance, while others may increase sensitivity, offering potential markers for predicting chemotherapy response.

Area of Science:

  • Molecular oncology
  • Cancer drug development
  • Genetics and cancer biology

Background:

  • Predicting tumor response to anticancer drugs is crucial for effective chemotherapy and chemoradiotherapy.
  • Understanding how oncogenes affect drug sensitivity can lead to personalized treatment strategies.

Purpose of the Study:

  • To investigate the impact of viral or activated oncogenes on cellular sensitivity to various anticancer drugs.
  • To identify potential oncogene-based markers for predicting chemosensitivity in tumors.

Main Methods:

  • Utilized Syrian hamster Osaka-Kanazawa (SHOK) cells and their transfectants expressing specific oncogenes (c-myc, v-mos, v-fgr, H-ras, c-cot, K-ras).
  • Assessed drug sensitivity by comparing the IC50 values of oncogene-transfected cells against a pSV2Neo control.
  • Tested sensitivity to four anticancer drugs: bleomycin, cisplatin, adriamycin, and mitomycin C.

Main Results:

  • H-ras oncogene conferred resistance to bleomycin, cisplatin, and adriamycin, and K-ras to mitomycin C.
  • c-myc and v-fgr increased sensitivity to bleomycin; c-myc and c-cot increased sensitivity to adriamycin.
  • v-mos affected sensitivity to bleomycin and adriamycin, while c-cot impacted all four drugs tested.

Conclusions:

  • Different oncogenes differentially modulate sensitivity to anticancer drugs.
  • The expression patterns of specific oncogenes may serve as predictive markers for individual tumor chemosensitivity.
  • Findings highlight the potential for oncogene profiling in tailoring cancer therapy.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...